

Sponsor

Novartis

Generic Drug Name

QAX576

Therapeutic Area of Trial

Asthma

Approved Indication

Investigational

Protocol Number

CQAX576A2207

Title

A Multi-Center, Randomized, Double Blind, Placebo-controlled, 'add-on' study to investigate the efficacy and safety of 24 weeks intravenous treatment with QAX576 in patients (≥ 18 -75 years) with persistent asthma not adequately controlled with inhaled corticosteroids and long acting $\beta 2$ -agonists

Study Phase

Phase II

Study Start/End Dates

21-May-2010 (first patient first visit) to 10-Apr-2012 (last patient last visit)

Study Design/Methodology

This was a randomized, multi-center, parallel group, double-blind study where QAX576 or placebo (i.v. infusion) was added to GINA guidelines (2007) step 4/5 asthma therapy.

There was a one-week pre-screening period (when informed consent was obtained and current asthma medications were reviewed) followed by a two-week screening period to assess eligibility and to collect e-diary data. The eligible patients (who demonstrated inadequately controlled asthma on current treatment) were randomized to one of the treatment arms (QAX576 or placebo) for a 24-week treatment period which was followed by a 12-week safety follow-up period.

Two sub-studies (measurement of FeNO and collection of induced sputum samples) were conducted in a subset of eligible patients at selected sites.

Two interim analyses were performed, and an external DMC was set up to overview safety.

Centers

53 centers in 7 countries: Argentina (10), Belgium (6), Czech Republic (4), Germany (10), Poland (5), Russia (8), US (10)

Publication

None

Test Product (s), Dose(s), and Mode(s) of Administration

QAX576 150mg powder for solution and matched placebo were provided by Novartis in glass vials and delivered via intravenous fusion (2 hour infusion) every three weeks.

Statistical Methods

The superiority of QAX576 over placebo was evaluated by testing the following null hypothesis (H₀) versus the alternative hypothesis (H_a):

H₀: There is no difference in ACQ at Week 24 for patients treated with QAX576 compared to placebo.

H_a: There is a difference in ACQ at Week 24 for patients treated with QAX576 compared to placebo.

The primary efficacy variable (change in ACQ score following 24 weeks treatment) was analyzed using a mixed model for the patients in the Full analysis set (FAS). The model contained treatment as a fixed effect with the baseline ACQ average score as a covariate.

In case of a missing value at Week 24, the method of last observation carried forward (LOCF) was used to impute missing ACQ average scores. The analysis for the primary variable was repeated for the per-protocol (PP) population with/without LOCF and for the patients in the FAS without LOCF.

All secondary efficacy analyses were performed on the patient in the FAS only. All statistical tests were two-sided using a 5% significance level.

Study Population: Inclusion/Exclusion Criteria and Demographics**Key Inclusion Criteria:**

Patients were included who met the following criteria:

1. Adult male and female patients aged ≥ 18 -75 years (only surgically sterilized or postmenopausal female patients), who signed an Informed Consent form prior to any study related assessment, including any adjustments to asthma medication prior to the start of screening period.
2. Female patients:
 - a. surgically sterilized at least 6 months prior to study participation) or
 - b. postmenopausal (no regular bleeding for at least 1 year)
3. Patients with BMI index within the range of 18 to 39 inclusive
4. Patients with a diagnosis of asthma, ≥ 1 year duration and:
 - were on daily treatment with $> 500\mu\text{g}$ BDP ($>250\mu\text{g}$ b.i.d.), or equivalent, plus a LABA (b.i.d.) for ≥ 3 months prior to the start of screening period, that had been stable for at least 4 weeks prior to start of screening period

- asthma was not adequately controlled by current treatments
 - $FEV_1 \geq 40\%$ and $\leq 80\%$ of the predicted normal value for the patient, after withholding bronchodilators¹
 - To be included in the induced sputum sub study patients were required to have $FEV_1 \geq 55\%$ predicted during screening period
 - With demonstrated or documented increase of $\geq 12\%$ in FEV1 over their baseline value within 30 minutes of inhaling salbutamol/albuterol^{1,2}
5. Compliance with Electronic Peak Flow/e-diary device during the screening period* (at the investigators judgment the screening period could be extended to collect 14 days of acceptable e-PEF/e-diary data)

*Compliance was defined as $\geq 85\%$ of the ePEF assessments or $\geq 85\%$ of the morning or evening ediary sessions completed correctly in the 14 days prior to the randomization. Threshold was automatically calculated by the e-PEF/e-diary device.

¹Withholding of bronchodilators prior to spirometry: SABA ≥ 6 hrs and LABA, or fixed dose combinations of LABA and ICS, for ≥ 24 hours.

²Reversibility demonstrated at start of screening period or documented in the 12 months prior to start of screening period

Key Exclusion Criteria:

Patients were excluded who met the following criteria:

1. Smoking history of greater than 10 pack years or inhaled tobacco products within the six months period prior to start of screening period
2. Diagnosed with COPD as defined by GOLD guidelines 2008
3. Had an asthma attack/exacerbation requiring a change in maintenance ICS or OCS treatment, or short burst of systemic corticosteroids, within six weeks prior to start of screening period
4. Had a respiratory tract infection within six weeks prior to Visit 2*
5. Had a medical history (within the 3 months prior to Visit 1) that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study.
6. Had a history or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or an AST/ALT or INR of more than 1.5x ULN at Visit 2.
7. Had history of renal disease or creatinine level above the ULN at Visit 2.
8. Had fasting triglycerides over 300 mg/dl (3.39 mmol/L) at Visit 2.
9. Had active cancer or a history of cancer with less than 5 years disease-free survival time (except for localized basal cell carcinoma of the skin without metastases).
10. Had a history of schistosomiasis, or stool examination positive for ova or parasites (at Visit 2), or travel to an area endemic with schistosomiasis (in the 6 months prior to Visit 2), including but not limited to Southeast and Southwest Asia, South America and Africa. Travel to these areas was not allowed until at least 6 months after the last dose.

Maintenance Immunotherapy (desensitization) for allergies was allowed if maintenance dose had been administered for at least 3 months prior to Visit 2, and was expected to remain unchanged throughout the course of the study.

*Visit 2 was the start of the screening period

Participant Flow

Patient disposition in treatment phase (Randomized set)

Disposition/Reason	QAX576 N=129 n (%)	Placebo N=130 n (%)	Total N=259 n (%)
Completed treatment phase	117 (90.7)	115 (88.5)	232 (89.6)
Discontinued prior to treatment phase completion	12 (9.3)	15 (11.5)	27 (10.4)
Primary reason for not completing treatment phase			
Adverse event	3 (2.3)	2 (1.5)	5 (1.9)
Lack of efficacy	2 (1.6)	2 (1.5)	4 (1.5)
Lost to follow-up	1 (0.8)	2 (1.5)	3 (1.2)
Non-compliance with study treatment	0	1 (0.8)	1 (0.4)
Physician decision	1 (0.8)	2 (1.5)	3 (1.2)
Pregnancy	0	0	0
Protocol deviation	0	0	0
No longer requires treatment	0	0	0
Study terminated by sponsor	0	1 (0.8)	1 (0.4)
Technical problems	0	0	0
Subject/guardian decision	5 (3.9)	5 (3.8)	10 (3.9)
Death	0	0	0

Disposition/Reason	QAX576 N=129 n (%)	Placebo N=130 n (%)	Total N=259 n (%)
--------------------	--------------------------	---------------------------	-------------------------

Patient disposition in follow-up phase (randomized set)

Disposition/Reason	QAX576 N=117 n (%)	Placebo N=115 n (%)	Total N=232 n (%)
Completed Phase	116 (99.1)	114 (99.1)	230 (99.1)
Ongoing in Phase	0	0	0
Discontinued prior to phase completion	1 (0.9)	1 (0.9)	2 (0.9)
Primary reason for not completing study phase			
Adverse event	0	1 (0.9)	1 (0.4)
Lack of efficacy	0	0	0
Lost to follow-up	0	0	0
Non-compliance with study treatment	0	0	0
Physician decision	0	0	0
Pregnancy	0	0	0
Protocol deviation	0	0	0
No longer requires treatment	0	0	0
Study terminated by sponsor	0	0	0
Technical problems	0	0	0
Subject/guardian decision	1 (0.9)	0	1 (0.4)
Death	0	0	0
New therapy for study indication	0	0	0

Baseline Characteristics

Demographic Variable	QAX576 N=129	Placebo N=130	Total N=259
Age group (years)			
< 65	104 (80.6)	110 (84.6)	214 (82.6)
≥ 65	25 (19.4)	20 (15.4)	45 (17.4)
Age (years)			
n	129	130	259
Mean	54.2	51.5	52.9
SD	11.79	13.08	12.50
Minimum	21.0	19.0	19.0
Median	56.0	53.0	54.0

Demographic Variable	QAX576 N=129	Placebo N=130	Total N=259
Maximum	74.0	75.0	75.0
Sex			
Male	61 (47.3)	78 (60.0)	139 (53.7)
Female	68 (52.7)	52 (40.0)	120 (46.3)
Race			
Black	3 (2.3)	5 (3.8)	8 (3.1)
Caucasian	121 (93.8)	117 (90.0)	238 (91.9)
Asian	0	0	0
Native American	0	1 (0.8)	1 (0.4)
Pacific Islander	0	1 (0.8)	1 (0.4)
Other	5 (3.9)	6 (4.6)	11 (4.2)
Ethnicity			
Hispanic or Latino	19 (14.7)	20 (15.4)	39 (15.1)
Chinese	0	0	0
Japanese	0	0	0
Korean	0	0	0
Other East Asian	0	0	0
South East Asian	0	0	0
Indian	0	0	0
Pakistani	0	0	0
Other South Asian	0	0	0
West Asian	0	0	0
Russian	25 (19.4)	24 (18.5)	49 (18.9)
Mixed Ethnicity	0	1 (0.8)	1 (0.4)
Not reported	5 (3.9)	2 (1.5)	7 (2.7)
Unknown	1 (0.8)	4 (3.1)	5 (1.9)
Other	79 (61.2)	79 (60.8)	158 (61.0)
Weight (kg)			
n	129	130	259
Mean	82.2	84.2	83.2
SD	14.93	16.80	15.89
Minimum	49.0	48.0	48.0
Median	80.5	84.2	83.0
Maximum	125.0	132.0	132.0
Height (cm)			
n	129	130	259
Mean	168.1	170.2	169.1
SD	10.31	9.77	10.08
Minimum	142.0	146.0	142.0

Demographic Variable	QAX576 N=129	Placebo N=130	Total N=259
Median	168.0	171.0	170.0
Maximum	189.0	198.0	198.0
BMI (kg/m ²)			
n	129	130	259
Mean	29.0	29.1	29.0
SD	4.26	5.26	4.78
Minimum	18.1	18.6	18.1
Median	28.6	28.7	28.6
Maximum	38.6	39.6	39.6

Outcome Measures

Primary Outcome Result

Efficacy of QAX576A (6mg/kg i.v. infusion every three weeks) versus placebo when added to existing asthma therapy was measured by the asthma control questionnaire (ACQ) score following 24 weeks treatments in patients with inadequately controlled moderate to severe persistent asthma. Inadequate control was defined as an ACQ score of >1.5 at the end of the screening period.

Primary analysis of change from baseline in ACQ with LOCF at 24 weeks (Full analysis set and Per-protocol set)

Treatment	n	Baseline Mean (SE)	Treatment		Comparison	Treatment difference				
			LS Mean	SE		LS Mean	SE	95% CI	p-value	
Full Analysis Set										
QAX576 (N=129)	121	2.68 (0.058)	-0.80	0.118	QAX576 - Placebo	-0.19	0.103	(-0.389, 0.016)	0.0714	
Placebo (N=130)	122	2.75 (0.066)	-0.61	0.113						
Per Protocol set										
QAX576 (N=76)	74	2.75 (0.079)	-0.87	0.156	QAX576 - Placebo	-0.25	0.127	(-0.505, -0.001)	0.0495	
Placebo (N=80)	76	2.75 (0.079)	-0.61	0.147						

SE = standard error

Mixed model: ACQ change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline ACQ score as a covariate, and center nested within country as a random effect.

Key Secondary Outcome Result(s)

Efficacy of QAX576A (6mg/kg i.v. infusion every three weeks) versus placebo when added to existing asthma therapy measured by:

- The incidence rate of clinically significant asthma exacerbations over 24 weeks treatment (defined as a worsening of asthma leading to oral or parenteral corticosteroid use; or, for patients using regular maintenance oral corticosteroids (OCS) at screening, an increase in OCS use or parenteral corticosteroid use)

Clinically significant asthma exacerbations (without imputation) during the 24-week treatment period: Estimated between-treatment comparison (Full analysis set)

	QAX576 (N=129)	Placebo (N=130)
Patients with ≥ 1 event, n (%)	21 (16.3)	29 (22.3)
Ratio of exacerbation rates \$		
QAX576 vs. Placebo	0.501	
95% Confidence Interval	0.207 - 1.212	
p-value for ratio	0.124	
Number of asthma exacerbations - n (%)		
0	108 (83.7)	101 (77.7)
1	13 (10.1)	21 (16.2)
2	5 (3.9)	7 (5.4)
3	2 (1.6)	1 (0.8)
≥ 4	1 (0.8)	0 (0.0)
p-value (QAX576 vs. Placebo) *	0.646	
Total number of asthma exacerbations	33	38
Total number of weeks in treatment period	2961	3000
Mean number of exacerbations per 24-week period	0.27	0.30
Ratio of exacerbation rates #		
QAX576 vs. Placebo	0.794	
95% Confidence Interval	0.462 - 1.364	
p-value for ratio	0.401	

#Logistic & \$Poisson regression model with treatment, country, history of atopy, history of asthma exacerbation, maintenance oral steroid use as mixed effects and center nested within country as fixed effects.

* based on Cochran-Mantel-Haenszel test stratified for study stratification factors.

- The number/percent of patients with an absolute change from baseline in the ACQ score of at least 1.25 at Week 24

Asthma Control Questionnaire (ACQ) overall change in score (>1.25 and >0.5) from baseline with LOCF at Week 24: Comparisons between treatment (Full analysis set)

Treatment comparison	QAX576 n/M (%)	Placebo n/M (%)	Odds Ratio	95% Confidence Interval	p-value
Improvement >1.25					
QAX576 vs. Placebo	40/121 (33.1)	31/122 (25.4)	1.70	(0.87, 3.32)	0.1215
Improvement >0.5					
QAX576 vs. Placebo	86/121 (71.1)	72/122 (59.0)	1.85	(1.03, 3.33)	0.0397

Logistic regression model includes terms for treatment, country, history of atopy, history of asthma exacerbation, and OCS use at screening as fixed effects with center nested within country as a fixed effect. The model also contains baseline ACQ score as a covariate.

Odds ratio of QAX576 to placebo: OR > 1 favors QAX576.

n: The number of subjects who have a positive response.

M: The total number of subjects with response variable defined in the treatment group.

LOCF = Last observation carried forward (Only data collected at week 12 and afterwards is used for LOCF for week 24)

- The total symptom scores (sum of night time, morning, day time symptom scores) as measured by mean daily total symptom score recorded between clinic visits at Weeks 22-24

Analysis of change from baseline in asthma symptom scores during last 3 weeks of treatment phase (Full analysis set)

Treatment	n	Baseline Mean (SE)	Treatment		Comparison	Treatment difference				
			LS Mean	SE		LS Mean	SE	95% CI	p-value	
Total Symptom Score										
QAX576 (N=129)	112	2.7 (0.17)	-1.2	0.18	QAX576 - Placebo	0.0	0.16	(-0.28, 0.35)	0.8166	
Placebo (N=130)	109	2.9 (0.16)	-1.2	0.17						
Nighttime Symptoms										
QAX576 (N=129)	113	0.8 (0.07)	-0.5	0.07	QAX576 - Placebo	0.0	0.07	(-0.12, 0.13)	0.9420	
Placebo (N=130)	114	1.0 (0.07)	-0.5	0.07						
Morning Symptoms										
QAX576 (N=129)	113	0.5 (0.04)	-0.2	0.05	QAX576 - Placebo	0.0	0.04	(-0.09, 0.08)	0.9658	

Treatment	n	Baseline Mean (SE)	Treatment		Comparison	Treatment difference				
			LS Mean	SE		LS Mean	SE	95% CI	p-value	
Placebo (N=130)	114	0.5 (0.03)	-0.2	0.04						
Daytime Symptoms										
QAX576 (N=129)	115	1.4 (0.08)	-0.6	0.09	QAX576 - Placebo	-0.0	0.08	(-0.19, 0.13)	0.7240	
Placebo (N=130)	111	1.5 (0.08)	-0.6	0.08						

LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

Mixed model: Symptom score change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline symptom score as a covariate, and center nested within country as a random effect.

Baseline values are calculated as mean in the screening period (visits 2-3).

Baseline mean shown only for subjects with baseline and post-baseline measurements.

The total symptom score (sum of nighttime, morning and daytime symptoms) possible range is 0 (good) to 9 (bad).

Other secondary outcome measures

Efficacy of QAX576 (6 mg/kg i.v infusion every 3 weeks) compared to placebo when added to existing asthma therapy measured by:

- ACQ score after 6, 12 and 18 weeks of treatment and at 36 weeks (follow-up). In addition, to compare QAX576 with placebo with respect to the proportion of patients with change from baseline in ACQ score in the following categories: > 0 , > -0.5 and ≤ 0 , > -0.75 and ≤ -0.5 , > -1 and ≤ -0.75 , > -1.25 and ≤ -1 , and ≤ -1.25 , after 12 and 24 weeks of treatment

Analysis of change from baseline in ACQ by visit (Full analysis set)

Treatment	n	Baseline Mean (SE)	Treatment		Comparison	Treatment difference				
			LS Mean	SE		LS Mean	SE	95% CI	p-value	
Visit 5 (Week 6)										
QAX576 (N=129)	124	2.72 (0.061)	-0.54	0.101	QAX576 - Placebo	-0.12	0.091	(-0.301, 0.057)	0.1803	
Placebo (N=130)	127	2.78 (0.065)	-0.42	0.094						
Visit 7 (Week 12)										
QAX576 (N=129)	121	2.68 (0.058)	-0.80	0.110	QAX576 - Placebo	-0.27	0.102	(-0.471, -0.067)	0.0091	
Placebo (N=130)	121	2.74 (0.066)	-0.53	0.102						
Visit 9 (Week 18)										

Treatment	n	Baseline Mean (SE)	Treatment		Comparison	Treatment difference				
			LS Mean	SE		LS Mean	SE	95% CI	p-value	
QAX576 (N=129)	117	2.68 (0.060)	-0.93	0.109	QAX576 - Placebo	-0.23	0.103	(-0.434, -0.030)	0.0249	
Placebo (N=130)	113	2.78 (0.068)	-0.70	0.103						
Visit 11 (Week 24)										
QAX576 (N=129)	117	2.68 (0.060)	-0.81	0.120	QAX576 - Placebo	-0.19	0.104	(-0.391, 0.018)	0.0732	
Placebo (N=130)	116	2.78 (0.067)	-0.62	0.114						
Visit 12 (Week 36)										
QAX576 (N=129)	118	2.69 (0.059)	-0.90	0.124	QAX576 - Placebo	-0.18	0.107	(-0.394, 0.029)	0.0907	
Placebo (N=130)	116	2.78 (0.067)	-0.71	0.117						
36 Week - 24 Week										
QAX576 (N=129)	116	1.78 (0.082)	-0.08	0.091	QAX576 - Placebo	-0.07	0.085	(-0.241, 0.096)	0.3961	
Placebo (N=130)	116	2.04 (0.089)	-0.01	0.085						

LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

Mixed model: ACQ change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline ACQ score as a covariate, and center nested within country as a random effect. ACQ score: 0 = good control of asthma, 6 = poor control of asthma.

- The overall ACQ score is the average of 6 questions and the categorized pre-bronchodilator FEV₁ (in % of predicted FEV₁), of which at least 4 had to be available.
- The total symptom scores (sum of night time, morning, day time symptom scores) as measured by mean daily total symptom score recorded between clinic visits i.e. Weeks 1-3, 4-6, 7-9, 10-12, 13-15, 16-18, 19-21 and 25 to 36 (follow-up)
- Night time, morning, day time symptom scores, as assessed by mean daily total symptom score recorded between clinic visits (as for the total symptom score)

Mean Asthma symptom total scores by interval: Between-treatment comparisons for absolute change from baseline (Full analysis set)

Interval	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
0-3 Weeks	QAX576 (N=129)	124	2.8 (0.16)	-0.3	0.12	QAX - Placebo	0.1	0.11	(-0.07, 0.35)	0.1761
	Placebo (N=130)	127	2.9 (0.15)	-0.4	0.12					
3-6 Weeks	QAX576 (N=129)	122	2.8 (0.16)	-0.7	0.16	QAX - Placebo	0.2	0.12	(-0.09, 0.40)	0.2140
	Placebo (N=130)	125	2.9 (0.15)	-0.9	0.15					
6-9 Weeks	QAX576 (N=129)	120	2.8 (0.17)	-0.9	0.16	QAX - Placebo	-0.0	0.14	(-0.29, 0.24)	0.8676
	Placebo (N=130)	123	2.9 (0.15)	-0.9	0.15					
9-12 Weeks	QAX576 (N=129)	119	2.8 (0.17)	-1.0	0.15	QAX - Placebo	0.1	0.14	(-0.22, 0.32)	0.7213
	Placebo (N=130)	119	2.9 (0.16)	-1.0	0.14					
12-15 Weeks	QAX576 (N=129)	115	2.7 (0.17)	-1.0	0.17	QAX - Placebo	0.1	0.16	(-0.24, 0.39)	0.6331
	Placebo (N=130)	114	2.9 (0.16)	-1.1	0.16					
15-18 Weeks	QAX576 (N=129)	110	2.7 (0.17)	-1.2	0.17	QAX - Placebo	0.0	0.16	(-0.29, 0.32)	0.9052
	Placebo (N=130)	115	2.9 (0.16)	-1.2	0.16					
18-21 Weeks	QAX576 (N=129)	113	2.7 (0.17)	-1.2	0.18	QAX - Placebo	-0.0	0.16	(-0.36, 0.28)	0.7989
	Placebo (N=130)	110	2.9 (0.16)	-1.2	0.17					
21-24 Weeks	QAX576 (N=129)	112	2.7 (0.17)	-1.2	0.18	QAX - Placebo	0.0	0.16	(-0.28, 0.35)	0.8166
	Placebo (N=130)	109	2.9 (0.16)	-1.2	0.17					
24-27 Weeks	QAX576 (N=129)	107	2.8 (0.18)	-1.2	0.19	QAX - Placebo	0.1	0.17	(-0.26, 0.40)	0.6857
	Placebo (N=130)	107	2.9 (0.16)	-1.3	0.18					
27-30 Weeks	QAX576 (N=129)	102	2.8 (0.18)	-1.2	0.19	QAX - Placebo	0.1	0.17	(-0.24, 0.43)	0.5626
	Placebo (N=130)	98	2.9 (0.17)	-1.3	0.18					
30-33 Weeks	QAX576 (N=129)	105	2.8 (0.18)	-1.3	0.20	QAX - Placebo	0.1	0.18	(-0.24, 0.46)	0.5396
	Placebo (N=130)	97	3.0 (0.17)	-1.4	0.19					
33-36 Weeks	QAX576 (N=129)	102	2.7 (0.18)	-1.3	0.19	QAX - Placebo	0.1	0.17	(-0.23, 0.44)	0.5315
	Placebo (N=130)	96	3.0 (0.17)	-1.4	0.18					
33 to 36 Weeks - 21 to 24 Weeks	QAX576 (N=129)	101	1.5 (0.16)	-0.1	0.10	QAX - Placebo	-0.1	0.09	(-0.24, 0.13)	0.5609
	Placebo (N=130)	95	1.5 (0.15)	-0.1	0.10					

- LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.
- Mixed model: Symptom score change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline symptom score as a covariate, and center nested within country as a random effect.
- Baseline values are calculated as mean in the screening period (visits 2-3).
- Baseline mean shown only for subjects with baseline and post-baseline measurements.
- The average score for each time interval is defined as the sum of daily scores divided by the number of days where

e diary records have been made for that time interval, as long as there is at least 7 days of usable data.

- The total symptom score (sum of nighttime, morning and daytime symptoms) possible range is 0 (good) to 9 (bad).

Mean Asthma symptom nocturnal scores by interval: Between-treatment comparisons for absolute change from baseline (Full analysis set)

Interval	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
0-3 Weeks	QAX576 (N=129)	126	0.9 (0.07)	-0.1	0.05	QAX - Placebo	0.1	0.05	(-0.04, 0.15)	0.2643
	Placebo (N=130)	129	1.0 (0.07)	-0.2	0.05					
3-6 Weeks	QAX576 (N=129)	124	0.9 (0.07)	-0.3	0.07	QAX - Placebo	0.0	0.05	(-0.07, 0.15)	0.4852
	Placebo (N=130)	126	1.0 (0.07)	-0.3	0.06					
6-9 Weeks	QAX576 (N=129)	120	0.9 (0.08)	-0.4	0.07	QAX - Placebo	-0.0	0.06	(-0.14, 0.07)	0.5350
	Placebo (N=130)	125	1.0 (0.07)	-0.3	0.06					
9-12 Weeks	QAX576 (N=129)	121	0.8 (0.07)	-0.4	0.06	QAX - Placebo	0.0	0.06	(-0.11, 0.12)	0.9432
	Placebo (N=130)	122	1.0 (0.07)	-0.4	0.06					
12-15 Weeks	QAX576 (N=129)	118	0.8 (0.08)	-0.4	0.07	QAX - Placebo	0.0	0.06	(-0.11, 0.14)	0.8215
	Placebo (N=130)	117	1.0 (0.07)	-0.4	0.06					
15-18 Weeks	QAX576 (N=129)	116	0.8 (0.08)	-0.5	0.07	QAX - Placebo	0.0	0.06	(-0.12, 0.13)	0.9293
	Placebo (N=130)	115	1.0 (0.07)	-0.5	0.06					
18-21 Weeks	QAX576 (N=129)	117	0.8 (0.08)	-0.4	0.08	QAX - Placebo	0.0	0.07	(-0.13, 0.16)	0.8385
	Placebo (N=130)	113	1.0 (0.07)	-0.4	0.07					
21-24 Weeks	QAX576 (N=129)	113	0.8 (0.07)	-0.5	0.07	QAX - Placebo	0.0	0.07	(-0.12, 0.13)	0.9420
	Placebo (N=130)	114	1.0 (0.07)	-0.5	0.07					
24-27 Weeks	QAX576 (N=129)	111	0.8 (0.08)	-0.4	0.08	QAX - Placebo	0.0	0.07	(-0.13, 0.15)	0.8806
	Placebo (N=130)	111	1.0 (0.07)	-0.5	0.07					
27-30 Weeks	QAX576 (N=129)	108	0.8 (0.08)	-0.5	0.08	QAX - Placebo	0.0	0.07	(-0.13, 0.15)	0.8897
	Placebo (N=130)	105	1.0 (0.07)	-0.5	0.07					
30-33 Weeks	QAX576 (N=129)	110	0.8 (0.08)	-0.5	0.08	QAX - Placebo	-0.0	0.07	(-0.15, 0.13)	0.8374
	Placebo (N=130)	105	1.0 (0.07)	-0.5	0.07					
33-36 Weeks	QAX576 (N=129)	107	0.8 (0.08)	-0.5	0.08	QAX - Placebo	-0.0	0.07	(-0.14, 0.13)	0.9355
	Placebo (N=130)	103	1.0 (0.08)	-0.5	0.07					
33 to 36 Weeks - 21 to 24 Weeks	QAX576 (N=129)	106	0.4 (0.06)	0.0	0.04	QAX - Placebo	-0.0	0.04	(-0.10, 0.06)	0.6379
	Placebo (N=130)	102	0.5 (0.06)	0.0	0.04					

LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: Symptom score change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline symptom score as a covariate, and center nested within country as a random effect.

- Baseline values are calculated as mean in the screening period (visits 2-3).

- Baseline mean shown only for subjects with baseline and post-baseline measurements.

- The average score for each time interval is defined as the sum of daily scores divided by the number of days where

ed diary records have been made for that time interval, as long as there is at least 7 days of usable data.

- The total nocturnal score possible range is 0 to 4, higher score the worse the symptoms.

Mean Asthma symptom morning scores by interval: Between-treatment comparisons for absolute change from baseline (Full analysis set)

Interval	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
0-3 Weeks	QAX576 (N=129)	126	0.5 (0.03)	0.0	0.03	QAX - Placebo	0.0	0.03	(-0.01, 0.08)	0.1660
	Placebo (N=130)	129	0.5 (0.03)	0.0	0.02					
3-6 Weeks	QAX576 (N=129)	124	0.5 (0.03)	-0.1	0.04	QAX - Placebo	0.1	0.03	(-0.01, 0.11)	0.1283
	Placebo (N=130)	126	0.5 (0.03)	-0.1	0.03					
6-9 Weeks	QAX576 (N=129)	120	0.5 (0.03)	-0.1	0.04	QAX - Placebo	-0.0	0.04	(-0.09, 0.05)	0.6263
	Placebo (N=130)	125	0.5 (0.03)	-0.1	0.03					
9-12 Weeks	QAX576 (N=129)	121	0.5 (0.03)	-0.1	0.04	QAX - Placebo	0.0	0.04	(-0.07, 0.08)	0.8744
	Placebo (N=130)	122	0.5 (0.03)	-0.1	0.04					
12-15 Weeks	QAX576 (N=129)	118	0.5 (0.04)	-0.1	0.04	QAX - Placebo	0.0	0.04	(-0.07, 0.08)	0.8850
	Placebo (N=130)	117	0.5 (0.03)	-0.1	0.04					
15-18 Weeks	QAX576 (N=129)	116	0.5 (0.04)	-0.2	0.04	QAX - Placebo	0.0	0.04	(-0.07, 0.09)	0.8478
	Placebo (N=130)	115	0.5 (0.03)	-0.2	0.04					
18-21 Weeks	QAX576 (N=129)	117	0.5 (0.04)	-0.2	0.04	QAX - Placebo	0.0	0.04	(-0.09, 0.08)	0.9245
	Placebo (N=130)	113	0.5 (0.03)	-0.2	0.04					
21-24 Weeks	QAX576 (N=129)	113	0.5 (0.04)	-0.2	0.05	QAX - Placebo	0.0	0.04	(-0.09, 0.08)	0.9658
	Placebo (N=130)	114	0.5 (0.03)	-0.2	0.04					
24-27 Weeks	QAX576 (N=129)	111	0.5 (0.04)	-0.2	0.05	QAX - Placebo	0.0	0.04	(-0.07, 0.10)	0.7405
	Placebo (N=130)	111	0.5 (0.03)	-0.2	0.04					
27-30 Weeks	QAX576 (N=129)	108	0.5 (0.04)	-0.2	0.05	QAX - Placebo	0.0	0.04	(-0.06, 0.11)	0.6050
	Placebo (N=130)	105	0.5 (0.04)	-0.2	0.04					
30-33 Weeks	QAX576 (N=129)	110	0.5 (0.04)	-0.2	0.05	QAX - Placebo	0.0	0.05	(-0.07, 0.11)	0.6673
	Placebo (N=130)	105	0.5 (0.04)	-0.2	0.05					
33-36 Weeks	QAX576 (N=129)	107	0.5 (0.04)	-0.2	0.05	QAX - Placebo	0.0	0.05	(-0.06, 0.12)	0.5654
	Placebo (N=130)	103	0.5 (0.04)	-0.2	0.05					
33 to 36 Weeks - 21 to 24 Weeks	QAX576 (N=129)	106	0.3 (0.04)	0.0	0.03	QAX - Placebo	0.0	0.03	(-0.04, 0.07)	0.5713
	Placebo (N=130)	102	0.3 (0.04)	0.0	0.03					

LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: Symptom score change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline symptom score as a covariate, and center nested within country as a random effect.

- Baseline values are calculated as mean in the screening period (visits 2-3).

- Baseline mean shown only for subjects with baseline and post-baseline measurements.

- The average score for each time interval is defined as the sum of daily scores divided by the number of days where ed diary records have been made for that time interval, as long as there is at least 7 days of useable data.

- The total morning score possible range is 0 to 1, higher score the worse the symptoms.

Mean Asthma symptom daytime scores by interval: Between-treatment comparisons for absolute change from baseline (Full analysis set)

Interval	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
0-3 Weeks	QAX576 (N=129)	125	1.4 (0.08)	-0.1	0.06	QAX - Placebo	0.1	0.05	(-0.04, 0.17)	0.2201
	Placebo (N=130)	129	1.5 (0.07)	-0.2	0.06					
3-6 Weeks	QAX576 (N=129)	124	1.4 (0.08)	-0.4	0.08	QAX - Placebo	0.1	0.07	(-0.08, 0.18)	0.4604
	Placebo (N=130)	127	1.5 (0.07)	-0.4	0.08					
6-9 Weeks	QAX576 (N=129)	121	1.4 (0.08)	-0.5	0.09	QAX - Placebo	0.0	0.08	(-0.11, 0.19)	0.6200
	Placebo (N=130)	125	1.5 (0.07)	-0.5	0.08					
9-12 Weeks	QAX576 (N=129)	121	1.4 (0.08)	-0.5	0.08	QAX - Placebo	0.0	0.07	(-0.12, 0.17)	0.7130
	Placebo (N=130)	120	1.5 (0.07)	-0.5	0.08					
12-15 Weeks	QAX576 (N=129)	118	1.4 (0.08)	-0.5	0.09	QAX - Placebo	0.0	0.08	(-0.15, 0.17)	0.9095
	Placebo (N=130)	116	1.5 (0.08)	-0.6	0.08					
15-18 Weeks	QAX576 (N=129)	116	1.4 (0.08)	-0.6	0.09	QAX - Placebo	-0.0	0.08	(-0.17, 0.15)	0.8827
	Placebo (N=130)	115	1.5 (0.08)	-0.6	0.08					
18-21 Weeks	QAX576 (N=129)	115	1.4 (0.08)	-0.6	0.09	QAX - Placebo	-0.0	0.08	(-0.19, 0.14)	0.7603
	Placebo (N=130)	113	1.5 (0.08)	-0.5	0.08					
21-24 Weeks	QAX576 (N=129)	115	1.4 (0.08)	-0.6	0.09	QAX - Placebo	-0.0	0.08	(-0.19, 0.13)	0.7240
	Placebo (N=130)	111	1.5 (0.08)	-0.6	0.08					
24-27 Weeks	QAX576 (N=129)	110	1.4 (0.08)	-0.6	0.10	QAX - Placebo	0.0	0.09	(-0.13, 0.20)	0.6837
	Placebo (N=130)	109	1.5 (0.08)	-0.6	0.09					
27-30 Weeks	QAX576 (N=129)	109	1.4 (0.09)	-0.6	0.10	QAX - Placebo	0.1	0.09	(-0.12, 0.23)	0.5446
	Placebo (N=130)	105	1.5 (0.08)	-0.7	0.09					
30-33 Weeks	QAX576 (N=129)	108	1.4 (0.08)	-0.6	0.10	QAX - Placebo	0.0	0.09	(-0.14, 0.22)	0.6329
	Placebo (N=130)	103	1.5 (0.08)	-0.6	0.10					
33-36 Weeks	QAX576 (N=129)	109	1.4 (0.08)	-0.6	0.10	QAX - Placebo	-0.0	0.09	(-0.20, 0.16)	0.8521
	Placebo (N=130)	101	1.5 (0.08)	-0.6	0.09					
33 to 36 Weeks - 21 to 24 Weeks	QAX576 (N=129)	109	0.8 (0.08)	0.0	0.06	QAX - Placebo	-0.0	0.05	(-0.13, 0.07)	0.5816
	Placebo (N=130)	99	0.8 (0.07)	0.0	0.05					

LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: Symptom score change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline symptom score as a covariate, and center nested within country as a random effect.
- Baseline values are calculated as mean in the screening period (visits 2-3).
- Baseline mean shown only for subjects with baseline and post-baseline measurements.
- The average score for each time interval is defined as the sum of daily scores divided by the number of days where diary records have been made for that time interval, as long as there is at least 7 days of useable data.
- The total daytime score possible range is 0 to 4, higher score the worse the symptoms.

- Day time and night time rescue medication use, and total daily rescue medication use, as assessed by mean day time and mean night time SABA use (short acting β 2-agonist) recorded between clinic visits (as for the total symptom score)

Mean daily number of puffs of asthma rescue medication by interval: Between-treatment comparisons for absolute change from baseline (Full analysis set)

Interval	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
0-3 Weeks	QAX576 (N=129)	124	3.1 (0.25)	-0.4	0.16	QAX - Placebo	0.0	0.15	(-0.26, 0.34)	0.7910
	Placebo (N=130)	127	3.6 (0.27)	-0.5	0.15					
3-6 Weeks	QAX576 (N=129)	122	3.0 (0.24)	-1.2	0.24	QAX - Placebo	-0.4	0.20	(-0.76, 0.03)	0.0704
	Placebo (N=130)	125	3.5 (0.27)	-0.9	0.23					
6-9 Weeks	QAX576 (N=129)	120	3.1 (0.25)	-1.3	0.27	QAX - Placebo	-0.5	0.23	(-0.92, -0.02)	0.0416
	Placebo (N=130)	123	3.5 (0.27)	-0.9	0.25					
9-12 Weeks	QAX576 (N=129)	119	3.0 (0.24)	-1.4	0.24	QAX - Placebo	-0.4	0.22	(-0.85, 0.01)	0.0537
	Placebo (N=130)	119	3.6 (0.28)	-1.0	0.23					
12-15 Weeks	QAX576 (N=129)	115	2.9 (0.25)	-1.6	0.26	QAX - Placebo	-0.4	0.23	(-0.84, 0.08)	0.1075
	Placebo (N=130)	114	3.6 (0.29)	-1.2	0.24					
15-18 Weeks	QAX576 (N=129)	110	2.9 (0.25)	-1.7	0.27	QAX - Placebo	-0.5	0.25	(-0.99, -0.02)	0.0411
	Placebo (N=130)	115	3.5 (0.29)	-1.2	0.25					
18-21 Weeks	QAX576 (N=129)	113	2.9 (0.24)	-1.6	0.30	QAX - Placebo	-0.5	0.27	(-0.98, 0.08)	0.0918
	Placebo (N=130)	110	3.5 (0.28)	-1.1	0.29					
21-24 Weeks	QAX576 (N=129)	112	2.9 (0.25)	-1.5	0.30	QAX - Placebo	-0.4	0.26	(-0.95, 0.08)	0.0986
	Placebo (N=130)	109	3.4 (0.28)	-1.1	0.28					
24-27 Weeks	QAX576 (N=129)	107	2.9 (0.26)	-1.5	0.30	QAX - Placebo	-0.4	0.26	(-0.92, 0.11)	0.1220
	Placebo (N=130)	107	3.5 (0.28)	-1.1	0.28					
27-30 Weeks	QAX576 (N=129)	102	2.9 (0.26)	-1.6	0.33	QAX - Placebo	-0.5	0.29	(-1.06, 0.08)	0.0920
	Placebo (N=130)	98	3.5 (0.30)	-1.1	0.31					
30-33 Weeks	QAX576 (N=129)	105	2.9 (0.26)	-1.6	0.34	QAX - Placebo	-0.5	0.30	(-1.10, 0.08)	0.0890
	Placebo (N=130)	97	3.6 (0.30)	-1.1	0.32					
33-36 Weeks	QAX576 (N=129)	102	2.9 (0.26)	-1.8	0.31	QAX - Placebo	-0.6	0.28	(-1.13, -0.04)	0.0357
	Placebo (N=130)	96	3.5 (0.30)	-1.2	0.29					
33 to 36 Weeks - 21 to 24 Weeks	QAX576 (N=129)	101	1.4 (0.20)	-0.2	0.12	QAX - Placebo	-0.3	0.11	(-0.48, -0.04)	0.0184
	Placebo (N=130)	95	2.0 (0.25)	0.1	0.11					

LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: mean number of puffs change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline mean number of puffs as a covariate, and center nested within country as a random effect.

- Baseline values are calculated as mean in the screening period (visits 2-3).

- Baseline mean shown only for subjects with baseline and post-baseline measurements.

- The average score for each time interval is defined as the sum of puffs divided by the number of days where diary records have been made for that time interval, as long as there is at least 7 days of useable data.

**Mean Daytime number of puffs of asthma rescue medication by interval:
Between-treatment comparisons for absolute change from baseline (Full analysis set)**

Interval	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
0-3 Weeks	QAX576 (N=129)	125	1.9 (0.14)	-0.3	0.09	QAX - Placebo	-0.0	0.08	(-0.20, 0.13)	0.6557
	Placebo (N=130)	129	2.0 (0.15)	-0.3	0.08					
3-6 Weeks	QAX576 (N=129)	124	1.8 (0.14)	-0.8	0.13	QAX - Placebo	-0.2	0.11	(-0.43, 0.02)	0.0743
	Placebo (N=130)	127	2.0 (0.15)	-0.6	0.13					
6-9 Weeks	QAX576 (N=129)	121	1.9 (0.14)	-0.8	0.15	QAX - Placebo	-0.2	0.13	(-0.48, 0.04)	0.0994
	Placebo (N=130)	125	2.0 (0.15)	-0.6	0.14					
9-12 Weeks	QAX576 (N=129)	121	1.8 (0.14)	-0.9	0.15	QAX - Placebo	-0.3	0.13	(-0.51, 0.01)	0.0587
	Placebo (N=130)	120	2.0 (0.15)	-0.6	0.14					
12-15 Weeks	QAX576 (N=129)	118	1.8 (0.15)	-1.0	0.15	QAX - Placebo	-0.2	0.14	(-0.52, 0.04)	0.0871
	Placebo (N=130)	116	2.0 (0.16)	-0.7	0.14					
15-18 Weeks	QAX576 (N=129)	116	1.8 (0.14)	-1.0	0.16	QAX - Placebo	-0.3	0.15	(-0.59, -0.01)	0.0423
	Placebo (N=130)	115	2.0 (0.16)	-0.7	0.15					
18-21 Weeks	QAX576 (N=129)	115	1.7 (0.14)	-0.9	0.18	QAX - Placebo	-0.3	0.16	(-0.59, 0.04)	0.0915
	Placebo (N=130)	113	2.1 (0.16)	-0.6	0.16					
21-24 Weeks	QAX576 (N=129)	115	1.8 (0.14)	-0.9	0.17	QAX - Placebo	-0.3	0.16	(-0.62, -0.00)	0.0487
	Placebo (N=130)	111	1.9 (0.15)	-0.6	0.16					
24-27 Weeks	QAX576 (N=129)	110	1.8 (0.14)	-0.9	0.18	QAX - Placebo	-0.3	0.15	(-0.55, 0.05)	0.1074
	Placebo (N=130)	109	2.0 (0.15)	-0.6	0.16					
27-30 Weeks	QAX576 (N=129)	109	1.7 (0.15)	-0.9	0.19	QAX - Placebo	-0.3	0.17	(-0.59, 0.07)	0.1152
	Placebo (N=130)	105	2.0 (0.15)	-0.7	0.18					
30-33 Weeks	QAX576 (N=129)	108	1.7 (0.15)	-0.9	0.19	QAX - Placebo	-0.3	0.17	(-0.61, 0.07)	0.1200
	Placebo (N=130)	103	2.0 (0.16)	-0.6	0.18					
33-36 Weeks	QAX576 (N=129)	109	1.8 (0.15)	-1.0	0.18	QAX - Placebo	-0.4	0.16	(-0.71, -0.07)	0.0180
	Placebo (N=130)	101	2.0 (0.16)	-0.7	0.17					
33 to 36 Weeks - 21 to 24 Weeks	QAX576 (N=129)	109	0.9 (0.12)	-0.2	0.07	QAX - Placebo	-0.2	0.07	(-0.32, -0.03)	0.0157
	Placebo (N=130)	99	1.3 (0.16)	0.0	0.07					

LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: mean number of puffs change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline mean number of puffs as a covariate, and center nested within country as a random effect.

- Baseline values are calculated as mean in the screening period (visits 2-3).

- Baseline mean shown only for subjects with baseline and post-baseline measurements.

- The average score for each time interval is defined as the sum of puffs divided by the number of days where

diary records have been made for that time interval, as long as there is at least 7 days of useable data.

**Mean Nighttime number of puffs of asthma rescue medication by interval:
Between-treatment comparisons for absolute change from baseline (Full analysis set)**

Interval	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			p-value
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	
0-3 Weeks	QAX576 (N=129)	126	1.2 (0.11)	-0.1	0.08	QAX - Placebo	0.0	0.08	(-0.11, 0.20)	0.5946
	Placebo (N=130)	129	1.6 (0.13)	-0.1	0.08					
3-6 Weeks	QAX576 (N=129)	124	1.2 (0.11)	-0.5	0.12	QAX - Placebo	-0.2	0.10	(-0.39, 0.01)	0.0608
	Placebo (N=130)	126	1.5 (0.13)	-0.3	0.11					
6-9 Weeks	QAX576 (N=129)	120	1.2 (0.11)	-0.6	0.13	QAX - Placebo	-0.3	0.11	(-0.46, -0.03)	0.0263
	Placebo (N=130)	125	1.5 (0.13)	-0.3	0.12					
9-12 Weeks	QAX576 (N=129)	121	1.2 (0.11)	-0.6	0.12	QAX - Placebo	-0.2	0.11	(-0.40, 0.02)	0.0740
	Placebo (N=130)	122	1.5 (0.13)	-0.4	0.11					
12-15 Weeks	QAX576 (N=129)	118	1.2 (0.11)	-0.6	0.12	QAX - Placebo	-0.2	0.10	(-0.37, 0.04)	0.1228
	Placebo (N=130)	117	1.5 (0.13)	-0.5	0.11					
15-18 Weeks	QAX576 (N=129)	116	1.1 (0.11)	-0.7	0.12	QAX - Placebo	-0.2	0.11	(-0.42, 0.00)	0.0541
	Placebo (N=130)	115	1.5 (0.13)	-0.5	0.11					
18-21 Weeks	QAX576 (N=129)	117	1.1 (0.11)	-0.7	0.13	QAX - Placebo	-0.2	0.12	(-0.43, 0.05)	0.1257
	Placebo (N=130)	113	1.6 (0.14)	-0.5	0.13					
21-24 Weeks	QAX576 (N=129)	113	1.1 (0.11)	-0.7	0.13	QAX - Placebo	-0.2	0.12	(-0.41, 0.05)	0.1321
	Placebo (N=130)	114	1.6 (0.14)	-0.5	0.13					
24-27 Weeks	QAX576 (N=129)	111	1.1 (0.12)	-0.7	0.13	QAX - Placebo	-0.2	0.12	(-0.44, 0.02)	0.0713
	Placebo (N=130)	111	1.5 (0.13)	-0.5	0.12					
27-30 Weeks	QAX576 (N=129)	108	1.1 (0.12)	-0.7	0.14	QAX - Placebo	-0.2	0.13	(-0.45, 0.05)	0.1097
	Placebo (N=130)	105	1.6 (0.14)	-0.5	0.13					
30-33 Weeks	QAX576 (N=129)	110	1.1 (0.12)	-0.7	0.14	QAX - Placebo	-0.2	0.13	(-0.50, 0.02)	0.0673
	Placebo (N=130)	105	1.6 (0.14)	-0.4	0.13					
33-36 Weeks	QAX576 (N=129)	107	1.1 (0.12)	-0.7	0.14	QAX - Placebo	-0.3	0.13	(-0.53, -0.03)	0.0302
	Placebo (N=130)	103	1.6 (0.14)	-0.5	0.13					
33 to 36 Weeks - 21 to 24 Weeks	QAX576 (N=129)	106	0.6 (0.08)	-0.1	0.06	QAX - Placebo	-0.1	0.06	(-0.24, -0.02)	0.0192
	Placebo (N=130)	102	0.9 (0.12)	0.1	0.05					

LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: mean number of puffs change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline mean number of puffs as a covariate, and center nested within country as a random effect.

- Baseline values are calculated as mean in the screening period (visits 2-3).

- Baseline mean shown only for subjects with baseline and post-baseline measurements.

- The average score for each time interval is defined as the sum of puffs divided by the number of days where diary records have been made for that time interval, as long as there is at least 7 days of useable data.

Percentage of days with no rescue medication use by interval: Between-treatment comparisons for absolute change from baseline (Full analysis set)

Interval	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
0-3 Weeks	QAX576 (N=129)	66	45.8 (4.06)	10.4	5.01	QAX - Placebo	-0.1	4.72	(-9.47, 9.25)	0.9815
	Placebo (N=130)	55	51.2 (4.73)	10.5	5.10					
3-6 Weeks	QAX576 (N=129)	67	45.2 (3.99)	20.2	4.73	QAX - Placebo	-0.7	4.63	(-9.83, 8.52)	0.8883
	Placebo (N=130)	58	49.5 (4.58)	20.9	4.79					
6-9 Weeks	QAX576 (N=129)	61	46.7 (4.23)	21.3	5.50	QAX - Placebo	-0.2	4.92	(-9.91, 9.59)	0.9744
	Placebo (N=130)	54	50.5 (4.75)	21.4	5.31					
9-12 Weeks	QAX576 (N=129)	67	45.2 (3.99)	22.9	5.03	QAX - Placebo	-0.3	4.99	(-10.21, 9.57)	0.9488
	Placebo (N=130)	54	49.5 (4.76)	23.3	5.12					
12-15 Weeks	QAX576 (N=129)	66	45.6 (4.03)	23.7	5.30	QAX - Placebo	-1.9	5.16	(-12.16, 8.28)	0.7073
	Placebo (N=130)	51	50.0 (4.89)	25.7	5.36					
15-18 Weeks	QAX576 (N=129)	63	45.3 (4.23)	21.7	5.10	QAX - Placebo	-4.6	5.14	(-14.80, 5.58)	0.3712
	Placebo (N=130)	51	52.8 (4.83)	26.3	5.09					
18-21 Weeks	QAX576 (N=129)	63	45.4 (4.22)	26.0	5.53	QAX - Placebo	-2.1	5.49	(-12.95, 8.83)	0.7083
	Placebo (N=130)	48	52.0 (5.04)	28.0	5.64					
21-24 Weeks	QAX576 (N=129)	67	43.6 (3.99)	25.2	5.56	QAX - Placebo	-8.9	5.34	(-19.51, 1.68)	0.0982
	Placebo (N=130)	49	51.7 (5.06)	34.1	5.81					
24-27 Weeks	QAX576 (N=129)	60	46.2 (4.29)	26.6	5.83	QAX - Placebo	-2.3	5.68	(-13.54, 9.02)	0.6915
	Placebo (N=130)	48	51.0 (5.08)	28.8	5.82					
27-30 Weeks	QAX576 (N=129)	56	46.9 (4.46)	28.2	5.18	QAX - Placebo	-1.0	5.34	(-11.61, 9.60)	0.8504
	Placebo (N=130)	43	50.8 (5.37)	29.2	5.13					
30-33 Weeks	QAX576 (N=129)	58	46.1 (4.32)	27.7	5.71	QAX - Placebo	-4.0	5.71	(-15.31, 7.38)	0.4889
	Placebo (N=130)	41	50.5 (5.55)	31.7	5.71					
33-36 Weeks	QAX576 (N=129)	61	44.4 (4.27)	32.8	4.98	QAX - Placebo	-1.8	5.14	(-12.01, 8.41)	0.7273
	Placebo (N=130)	42	51.8 (5.40)	34.6	5.19					
33 to 36 Weeks - 21 to 24 Weeks	QAX576 (N=129)	74	75.7 (3.43)	4.8	3.44	QAX - Placebo	3.6	3.32	(-3.01, 10.14)	0.2853
	Placebo (N=130)	58	82.2 (3.20)	1.2	3.40					

- LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: percentage of days with no rescue med use change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline symptom score as a covariate, and center nested within country as a random effect.

- Baseline values are calculated as mean in the screening period (visits 2-3).

- Baseline mean shown only for subjects with baseline and post-baseline measurements.

- The average score for each time interval is defined as the sum of number of days with no rescue medication use divided by the number of days where diary records have been made for that time interval, as long as there is at least 7 days of useable data.

- FEV₁ and FVC measured at the clinic visits prior to dosing after 6, 12, 18, and 24 weeks of treatment and at 36 weeks (follow-up)

FEV1 (L) without LOCF by visit: Between-treatment comparisons for absolute change from baseline (Full analysis set)

Visit	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
Visit 5 (Week 6)	QAX576 (N=129)	114	1.782 (0.0604)	0.108	0.0541	QAX - Placebo	0.025	0.0468	(-0.0671, 0.1173)	0.5925
	Placebo (N=130)	120	1.869 (0.0561)	0.083	0.0509					
Visit 7 (Week 12)	QAX576 (N=129)	112	1.788 (0.0615)	0.063	0.0582	QAX - Placebo	0.022	0.0546	(-0.0853, 0.1299)	0.6833
	Placebo (N=130)	113	1.835 (0.0574)	0.041	0.0528					
Visit 9 (Week 18)	QAX576 (N=129)	104	1.813 (0.0654)	0.160	0.0578	QAX - Placebo	0.077	0.0531	(-0.0276, 0.1820)	0.1480
	Placebo (N=130)	109	1.851 (0.0609)	0.083	0.0536					
Visit 11 (Week 24)	QAX576 (N=129)	109	1.737 (0.0590)	0.059	0.0543	QAX - Placebo	0.052	0.0508	(-0.0483, 0.1522)	0.3084
	Placebo (N=130)	107	1.893 (0.0624)	0.008	0.0497					
Visit 12 (Week 36)	QAX576 (N=129)	106	1.762 (0.0619)	0.118	0.0590	QAX - Placebo	0.093	0.0571	(-0.0191, 0.2059)	0.1033
	Placebo (N=130)	106	1.905 (0.0616)	0.025	0.0542					
36 Week - 24 Week	QAX576 (N=129)	107	1.877 (0.0693)	0.063	0.0409	QAX - Placebo	0.060	0.0393	(-0.0180, 0.1371)	0.1316
	Placebo (N=130)	106	1.966 (0.0677)	0.004	0.0376					

- Spirometry measurements taken within 6 hours of a SABA or within 24 hours of a LABA are excluded.
- Mixed model: FEV1 change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline FEV1 as a covariate, and center nested within country as a random effect.
- Baseline is defined as the value at visit 3.

FEV1 (L) without LOCF by visit: Between-treatment comparisons for percent change from baseline (Full analysis set)

Visit	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
Visit 5 (Week 6)	QAX576 (N=129)	114	1.782 (0.0604)	12.149	5.1321	QAX - Placebo	3.913	2.6664	(-1.3490, 9.1744)	0.1440
	Placebo (N=130)	120	1.869 (0.0561)	8.236	5.0202					
Visit 7 (Week 12)	QAX576 (N=129)	112	1.788 (0.0615)	6.229	3.7456	QAX - Placebo	1.821	3.5111	(-5.1002, 8.7416)	0.6046
	Placebo (N=130)	113	1.835 (0.0574)	4.408	3.4000					
Visit 9 (Week 18)	QAX576 (N=129)	104	1.813 (0.0654)	10.635	3.8177	QAX - Placebo	4.202	3.3681	(-2.4407, 10.8446)	0.2137
	Placebo (N=130)	109	1.851 (0.0609)	6.433	3.5802					
Visit 11 (Week 24)	QAX576 (N=129)	109	1.737 (0.0590)	5.248	3.5169	QAX - Placebo	1.532	3.2955	(-4.9660, 8.0291)	0.6426
	Placebo (N=130)	107	1.893 (0.0624)	3.716	3.2211					
Visit 12 (Week 36)	QAX576 (N=129)	106	1.762 (0.0619)	8.467	3.5882	QAX - Placebo	4.041	3.4704	(-2.8024, 10.8840)	0.2457
	Placebo (N=130)	106	1.905 (0.0616)	4.426	3.2946					
36 Week - 24 Week	QAX576 (N=129)	107	1.877 (0.0693)	4.302	2.2491	QAX - Placebo	3.023	2.1612	(-1.2382, 7.2850)	0.1634
	Placebo (N=130)	106	1.966 (0.0677)	1.279	2.0679					

- Spirometry measurements taken within 6 hours of a SABA or within 24 hours of a LABA are excluded.

- Mixed model: FEV1 % change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline FEV1 as a covariate, and center nested within country as a random effect.
- Baseline is defined as the value at visit 3.

% Predicted FEV1 without LOCF by visit: Between-treatment comparisons for absolute change from baseline (Full analysis set)

Visit	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
Visit 5 (Week 6)	QAX576 (N=129)	114	60.978 (1.2258)	3.774	1.6423	QAX - Placebo	1.809	1.4698	(-1.0882, 4.7062)	0.2198
	Placebo (N=130)	120	60.345 (1.2363)	1.965	1.5416					
Visit 7 (Week 12)	QAX576 (N=129)	112	61.373 (1.2961)	2.672	1.8426	QAX - Placebo	1.939	1.7411	(-1.4936, 5.3706)	0.2668
	Placebo (N=130)	113	60.168 (1.3075)	0.733	1.6802					
Visit 9 (Week 18)	QAX576 (N=129)	104	61.946 (1.3259)	5.320	1.8426	QAX - Placebo	3.353	1.6765	(0.0473, 6.6596)	0.0468
	Placebo (N=130)	109	59.965 (1.3139)	1.966	1.7289					
Visit 11 (Week 24)	QAX576 (N=129)	109	61.088 (1.2994)	2.198	1.7093	QAX - Placebo	2.079	1.6123	(-1.1001, 5.2578)	0.1987
	Placebo (N=130)	107	60.362 (1.2821)	0.119	1.5918					
Visit 12 (Week 36)	QAX576 (N=129)	106	61.073 (1.3315)	4.387	1.8516	QAX - Placebo	3.535	1.8062	(-0.0263, 7.0970)	0.0517
	Placebo (N=130)	106	60.611 (1.2906)	0.851	1.7258					
36 Week - 24 Week	QAX576 (N=129)	107	64.935 (1.4832)	2.591	1.3141	QAX - Placebo	2.525	1.2804	(0.0007, 5.0500)	0.0499
	Placebo (N=130)	106	62.801 (1.5971)	0.065	1.2292					

- Spirometry measurements taken within 6 hours of a SABA or within 24 hours of a LABA are excluded.
- Mixed model: % predicted FEV1 change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline FEV1 as a covariate, and center nested within country as a random effect.
- Baseline is defined as the value at visit 3.

FVC (L) without LOCF by visit: Between-treatment comparisons for absolute change from baseline (Full analysis set)

Visit	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
Visit 5 (Week 6)	QAX576 (N=129)	114	3.090 (0.0964)	0.096	0.0591	QAX - Placebo	0.046	0.0545	(-0.0615, 0.1535)	0.3997
	Placebo (N=130)	120	3.266 (0.0909)	0.050	0.0545					
Visit 7 (Week 12)	QAX576 (N=129)	112	3.086 (0.0952)	0.059	0.0723	QAX - Placebo	0.046	0.0654	(-0.0830, 0.1748)	0.4833
	Placebo (N=130)	113	3.210 (0.0932)	0.013	0.0661					
Visit 9 (Week 18)	QAX576 (N=129)	104	3.159 (0.1020)	0.168	0.0723	QAX - Placebo	0.104	0.0644	(-0.0226, 0.2316)	0.1065
	Placebo (N=130)	109	3.232 (0.0974)	0.063	0.0678					
Visit 11 (Week 24)	QAX576 (N=129)	109	3.043 (0.0927)	0.016	0.0601	QAX - Placebo	0.078	0.0565	(-0.0328, 0.1898)	0.1660
	Placebo (N=130)	107	3.300 (0.0988)	-0.062	0.0552					
Visit 12 (Week 36)	QAX576 (N=129)	106	3.072 (0.0980)	0.134	0.0683	QAX - Placebo	0.146	0.0660	(0.0161, 0.2764)	0.0278
	Placebo (N=130)	106	3.298 (0.0978)	-0.012	0.0628					
36 Week - 24 Week	QAX576 (N=129)	107	3.182 (0.1054)	0.117	0.0531	QAX - Placebo	0.084	0.0506	(-0.0153, 0.1840)	0.0968
	Placebo (N=130)	106	3.327 (0.0956)	0.033	0.0489					

- Spirometry measurements taken within 6 hours of a SABA or within 24 hours of a LABA are excluded.

- Mixed model: FVC change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline FVC as a covariate, and center nested within country as a random effect.
- Baseline is defined as the value at visit 3.

- PEF (AM and PM) as assessed by mean morning and mean evening PEF (peak expiratory flow) recorded between clinic visits

Mean Morning PEF (L/min) by interval: Between-treatment comparisons for change from baseline (Full analysis set)

Interval	Treatment	n	Baseline Mean (SE)	Treatment		Comparison	Treatment difference			
				LS Mean	SE		LS Mean	SE	95% CI	p-value
0-3 Weeks	QAX576 (N=129)	126	287.7 (9.62)	3.0	4.23	QAX - Placebo	3.5	4.06	(-4.52, 11.47)	0.3931
	Placebo (N=130)	129	321.9 (11.79)	-0.5	3.90					
3-6 Weeks	QAX576 (N=129)	124	288.5 (9.70)	7.6	5.92	QAX - Placebo	7.7	5.51	(-3.19, 18.50)	0.1659
	Placebo (N=130)	126	323.4 (11.96)	-0.1	5.52					
6-9 Weeks	QAX576 (N=129)	120	290.1 (9.98)	9.5	6.87	QAX - Placebo	10.1	6.37	(-2.44, 22.66)	0.1139
	Placebo (N=130)	125	327.0 (11.83)	-0.7	6.29					
9-12 Weeks	QAX576 (N=129)	121	290.5 (9.83)	15.0	6.79	QAX - Placebo	10.4	6.41	(-2.25, 23.01)	0.1067
	Placebo (N=130)	122	322.5 (11.99)	4.6	6.27					
12-15 Weeks	QAX576 (N=129)	118	290.8 (9.97)	17.7	6.77	QAX - Placebo	12.0	6.44	(-0.74, 24.64)	0.0647
	Placebo (N=130)	117	321.8 (12.43)	5.7	6.21					
15-18 Weeks	QAX576 (N=129)	116	293.1 (10.13)	20.6	7.10	QAX - Placebo	17.3	6.73	(3.99, 30.54)	0.0110
	Placebo (N=130)	115	322.7 (12.45)	3.3	6.60					
18-21 Weeks	QAX576 (N=129)	117	292.6 (10.06)	17.9	7.65	QAX - Placebo	12.1	7.34	(-2.35, 26.57)	0.1002
	Placebo (N=130)	113	322.5 (12.61)	5.8	7.04					
21-24 Weeks	QAX576 (N=129)	113	291.0 (10.33)	16.3	7.65	QAX - Placebo	13.4	7.34	(-1.07, 27.86)	0.0694
	Placebo (N=130)	114	324.9 (12.57)	3.0	7.01					
24-27 Weeks	QAX576 (N=129)	111	287.5 (10.12)	18.7	7.82	QAX - Placebo	9.8	7.35	(-4.74, 24.24)	0.1860
	Placebo (N=130)	111	324.9 (12.74)	8.9	7.16					
27-30 Weeks	QAX576 (N=129)	108	284.8 (10.07)	18.5	7.93	QAX - Placebo	9.5	7.42	(-5.17, 24.09)	0.2036
	Placebo (N=130)	105	321.4 (13.18)	9.1	7.33					
30-33 Weeks	QAX576 (N=129)	110	288.0 (10.23)	17.0	8.31	QAX - Placebo	13.1	7.83	(-2.39, 28.49)	0.0970
	Placebo (N=130)	105	324.0 (13.01)	4.0	7.68					
33-36 Weeks	QAX576 (N=129)	107	288.8 (10.47)	16.5	8.74	QAX - Placebo	12.7	8.40	(-3.90, 29.22)	0.1334
	Placebo (N=130)	103	325.6 (13.36)	3.8	8.28					
33 to 36 Weeks - 21 to 24 Weeks	QAX576 (N=129)	106	308.0 (11.73)	-0.3	4.76	QAX - Placebo	2.0	4.56	(-7.01, 10.99)	0.6629
	Placebo (N=130)	102	330.2 (13.20)	-2.3	4.53					

- LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: mean PEF change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline mean PEF as covariate, center nested within country as random effect.

- Baseline values are calculated as mean in the screening period (visits 2-3).

- Baseline mean shown only for subjects with baseline and post-baseline measurements.

- The average score for each time interval is defined as the sum of daily PEF measures divided by the number of days where diary records have been made for that time interval, as long as there is at least 7 days of useable data.

- The total symptom score (sum of nighttime, morning and daytime symptoms) possible range is 0 (good) to 9 (bad).
- Only the data where rescue medication has not been taken within 6 hours of the PEF measurement is included.

Mean Evening PEF (L/min) by interval: Between-treatment comparisons for change from baseline (Full analysis set)

0-3 Weeks	QAX576	125	309.7	-3.2	4.62	QAX - Placebo	1.1	4.36 (-7.49,	9.68)	0.8020
	(N=129)		(10.23)								
	Placebo	129	335.2	-4.3	4.29						
	(N=130)		(11.86)								
3-6 Weeks	QAX576	124	307.7	-2.5	5.82	QAX - Placebo	-0.1	5.45 (-10.81,	10.67)	0.9897
	(N=129)		(10.26)								
	Placebo	127	337.3	-2.4	5.39						
	(N=130)		(11.91)								
6-9 Weeks	QAX576	121	309.0	2.1	6.66	QAX - Placebo	5.1	6.09 (-6.96,	17.06)	0.4080
	(N=129)		(10.45)								
	Placebo	125	340.5	-2.9	6.12						
	(N=130)		(11.87)								
9-12 Weeks	QAX576	121	309.3	5.2	7.28	QAX - Placebo	8.6	6.70 (-4.57,	21.86)	0.1987
	(N=129)		(10.44)								
	Placebo	120	336.2	-3.4	6.83						
	(N=130)		(12.32)								
12-15 Weeks	QAX576	118	309.4	8.0	7.07	QAX - Placebo	9.9	6.63 (-3.20,	22.93)	0.1382
	(N=129)		(10.67)								
	Placebo	116	334.9	-1.8	6.53						
	(N=130)		(12.63)								
15-18 Weeks	QAX576	116	311.7	2.7	7.82	QAX - Placebo	9.9	7.43 (-4.70,	24.58)	0.1821
	(N=129)		(10.76)								
	Placebo	115	337.5	-7.2	7.29						
	(N=130)		(12.62)								
18-21 Weeks	QAX576	115	310.7	4.2	8.27	QAX - Placebo	7.1	7.85 (-8.36,	22.58)	0.3661
	(N=129)		(10.85)								
	Placebo	113	337.9	-2.9	7.61						
	(N=130)		(12.88)								
21-24 Weeks	QAX576	115	311.4	1.2	7.97	QAX - Placebo	6.5	7.45 (-8.21,	21.14)	0.3863
	(N=129)		(10.87)								
	Placebo	111	338.2	-5.2	7.48						
	(N=130)		(13.05)								
24-27 Weeks	QAX576	110	307.3	4.7	8.45	QAX - Placebo	3.6	7.75 (-11.69,	18.87)	0.6440
	(N=129)		(11.01)								
	Placebo	109	337.7	1.1	7.79						
	(N=130)		(13.10)								
27-30 Weeks	QAX576	109	308.5	-0.3	8.84	QAX - Placebo	4.9	8.17 (-11.24,	21.00)	0.5515
	(N=129)		(11.05)								
	Placebo	105	337.3	-5.2	8.15						
	(N=130)		(13.27)								
30-33 Weeks	QAX576	108	309.0	-2.2	9.00	QAX - Placebo	8.5	8.47 (-8.24,	25.18)	0.3189
	(N=129)		(11.13)								
	Placebo	103	337.6	-10.7	8.31						
	(N=130)		(13.41)								
33-36 Weeks	QAX576	109	307.5	-3.6	9.07	QAX - Placebo	8.5	8.53 (-8.28,	25.35)	0.3182
	(N=129)		(11.01)								
	Placebo	101	335.5	-12.2	8.55						
	(N=130)		(13.53)								
33 to 36 Weeks - 21 to 24 Weeks	QAX576	109	318.2	-7.0	4.75	QAX - Placebo	4.3	4.59 (-4.76,	13.35)	0.3509
	(N=129)		(11.50)								
	Placebo	99	336.4	-11.3	4.47						
	(N=130)		(13.22)								

- LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.
- Mixed model: mean PEF change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline mean PEF as covariate, center nested within country as random effect.
- Baseline values are calculated as mean in the screening period (visits 2-3).
- Baseline mean shown only for subjects with baseline and post-baseline measurements.
- The average score for each time interval is defined as the sum of daily PEF measures divided by the number of days where diary records have been made for that time interval, as long as there is at least 7 days of useable data.
- The total symptom score (sum of nighttime, morning and daytime symptoms) possible range is 0 (good) to 9 (bad).

- Only the data where rescue medication has not been taken within 6 hours of the PEF measurement is included.

- AQLQ (Asthma Quality of Life Questionnaire) scores as recorded at the clinic visit prior to all other assessments after 24 weeks of treatment and at 36 weeks (follow-up)

Mean AQLQ overall score by visit: Between-treatment comparisons for change from baseline (Full analysis set)

Visit	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
Visit 11 (Week 24)	QAX576 (N=129)	114	4.48 (0.100)	0.61	0.134	QAX - Placebo	0.12	0.110	(-0.099, 0.336)	0.2834
	Placebo (N=130)	113	4.17 (0.098)	0.49	0.130					
Visit 12 (Week 36)	QAX576 (N=129)	115	4.47 (0.098)	0.58	0.144	QAX - Placebo	-0.05	0.117	(-0.279, 0.183)	0.6836
	Placebo (N=130)	113	4.17 (0.098)	0.63	0.140					
36 Week - 24 Week	QAX576 (N=129)	113	5.19 (0.103)	-0.02	0.114	QAX - Placebo	-0.05	0.094	(-0.240, 0.132)	0.5697
	Placebo (N=130)	113	4.88 (0.099)	0.04	0.110					

- LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: AQLQ score change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline AQLQ score as a covariate, and center nested within country as a random effect.

- Score: 1 = totally limited/problems all time, 7 = not at all limited/no problems.

- Baseline mean shown only for subjects with baseline and post-baseline.

Mean AQLQ score from activities domain by visit: Between-treatment comparisons for change from baseline (Full analysis set)

Visit	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
Visit 11 (Week 24)	QAX576 (N=129)	114	4.35 (0.097)	0.82	0.147	QAX - Placebo	0.20	0.120	(-0.034, 0.441)	0.0932
	Placebo (N=130)	113	4.13 (0.107)	0.62	0.143					
Visit 12 (Week 36)	QAX576 (N=129)	115	4.35 (0.095)	0.72	0.152	QAX - Placebo	-0.08	0.126	(-0.325, 0.173)	0.5490
	Placebo (N=130)	113	4.13 (0.107)	0.80	0.147					
36 Week - 24 Week	QAX576 (N=129)	113	5.21 (0.106)	-0.07	0.121	QAX - Placebo	-0.15	0.103	(-0.354, 0.053)	0.1465
	Placebo (N=130)	113	4.91 (0.106)	0.08	0.117					

- LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: AQLQ score change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline AQLQ score as a covariate, and center nested within country as a random effect.

- Score: 1 = totally limited/problems all time, 7 = not at all limited/no problems.

- Baseline mean shown only for subjects with baseline and post-baseline.

Mean Mini-AQLQ score from emotions domain by visit: Between-treatment comparisons for change from baseline (Full analysis set)

Visit	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			p-value
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	
Visit 11 (Week 24)	QAX576 (N=129)	114	4.53 (0.103)	0.53	0.135	QAX - Placebo	0.08	0.112	(-0.144, 0.296)	0.4970
	Placebo (N=130)	113	4.21 (0.099)	0.45	0.130					
Visit 12 (Week 36)	QAX576 (N=129)	115	4.51 (0.100)	0.50	0.149	QAX - Placebo	-0.04	0.119	(-0.275, 0.195)	0.7360
	Placebo (N=130)	113	4.21 (0.099)	0.54	0.145					
36 Week - 24 Week	QAX576 (N=129)	113	5.16 (0.106)	-0.02	0.116	QAX - Placebo	-0.02	0.097	(-0.208, 0.175)	0.8654
	Placebo (N=130)	113	4.88 (0.101)	0.00	0.113					

- LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.
- Mixed model: AQLQ score change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline AQLQ score as a covariate, and center nested within country as a random effect.
- Score: 1 = totally limited/problems all time, 7 = not at all limited/no problems.
- Baseline mean shown only for subjects with baseline and post-baseline.

Mean AQLQ score from symptoms domain by visit: Between-treatment comparisons for change from baseline (Full analysis set)

Visit	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			p-value
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	
Visit 11 (Week 24)	QAX576 (N=129)	114	4.75 (0.130)	0.49	0.173	QAX - Placebo	0.18	0.144	(-0.107, 0.460)	0.2218
	Placebo (N=130)	113	4.30 (0.125)	0.31	0.168					
Visit 12 (Week 36)	QAX576 (N=129)	115	4.75 (0.128)	0.51	0.189	QAX - Placebo	0.03	0.160	(-0.283, 0.348)	0.8382
	Placebo (N=130)	112	4.29 (0.125)	0.47	0.185					
36 Week - 24 Week	QAX576 (N=129)	113	5.40 (0.118)	-0.01	0.153	QAX - Placebo	0.00	0.129	(-0.249, 0.258)	0.9715
	Placebo (N=130)	112	4.99 (0.125)	-0.01	0.152					

- LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.
- Mixed model: AQLQ score change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline AQLQ score as a covariate, and center nested within country as a random effect.
- Score: 1 = totally limited/problems all time, 7 = not at all limited/no problems.
- Baseline mean shown only for subjects with baseline and post-baseline.

Mean AQLQ score from environmental exposure domain by visit: Between-treatment comparisons for change from baseline (Full analysis set)

Visit	Treatment	n	Baseline	Treatment		Comparison	Treatment difference			
			Mean (SE)	LS Mean	SE		LS Mean	SE	95% CI	p-value
Visit 11 (Week 24)	QAX576 (N=129)	114	4.36 (0.139)	0.44	0.147	QAX - Placebo	0.03	0.131	(-0.231, 0.286)	0.8323
	Placebo (N=130)	113	4.02 (0.121)	0.41	0.140					
Visit 12 (Week 36)	QAX576 (N=129)	115	4.35 (0.136)	0.55	0.171	QAX - Placebo	0.03	0.141	(-0.252, 0.303)	0.8559
	Placebo (N=130)	113	4.02 (0.121)	0.53	0.165					
36 Week - 24 Week	QAX576 (N=129)	113	4.92 (0.121)	0.16	0.153	QAX - Placebo	0.10	0.125	(-0.141, 0.350)	0.4029
	Placebo (N=130)	113	4.69 (0.123)	0.06	0.149					

- LS Mean = least squares mean, SE = standard error of the mean, CI = confidence interval.

- Mixed model: AQLQ score change from baseline = treatment, country, history of atopy, history of asthma exacerbation, maintenance OCS use as fixed effects, baseline AQLQ score as a covariate, and center nested within country as a random effect.

- Score: 1 = totally limited/problems all time, 7 = not at all limited/no problems.

- Baseline mean shown only for subjects with baseline and post-baseline.

- Pharmacokinetic (QAX576) concentrations as measured in plasma samples taken at clinic visits in all patients following 6, 12, 21 and 24 weeks of treatment and at 36 weeks (follow-up). A population PK approach was used to derive PK parameters.

Note: PK results were not available at the time of final clinical study report (CSR) writing therefore PK secondary outcome measure results are not included here and will be published when available by updating this document.

Safety Results
Number (%) of patients with Adverse Events by System Organ Class (Safety set)

Primary system organ class	QAX576 N=129 n (%)	Placebo N=130 n (%)	Total N=259 n (%)
Number of subjects with at least one AE	75 (58.1)	79 (60.8)	154 (59.5)
Blood and lymphatic system disorders	2 (1.6)	0	2 (0.8)
Cardiac disorders	2 (1.6)	2 (1.5)	4 (1.5)
Congenital, familial and genetic disorders	1 (0.8)	0	1 (0.4)
Ear and labyrinth disorders	1 (0.8)	2 (1.5)	3 (1.2)
Endocrine disorders	1 (0.8)	1 (0.8)	2 (0.8)
Eye disorders	2 (1.6)	2 (1.5)	4 (1.5)
Gastrointestinal disorders	10 (7.8)	13 (10.0)	23 (8.9)
General disorders and administration site conditions	5 (3.9)	7 (5.4)	12 (4.6)
Infections and infestations	45 (34.9)	38 (29.2)	83 (32.0)
Injury, poisoning and procedural complications	5 (3.9)	6 (4.6)	11 (4.2)

Primary system organ class	QAX576 N=129 n (%)	Placebo N=130 n (%)	Total N=259 n (%)
Investigations	1 (0.8)	2 (1.5)	3 (1.2)
Metabolism and nutrition disorders	1 (0.8)	3 (2.3)	4 (1.5)
Musculoskeletal and connective tissue disorders	10 (7.8)	8 (6.2)	18 (6.9)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0	1 (0.8)	1 (0.4)
Nervous system disorders	9 (7.0)	12 (9.2)	21 (8.1)
Psychiatric disorders	2 (1.6)	1 (0.8)	3 (1.2)
Renal and urinary disorders	1 (0.8)	2 (1.5)	3 (1.2)
Respiratory, thoracic and mediastinal disorders	49 (38.0)	51 (39.2)	100 (38.6)
Skin and subcutaneous tissue disorders	5 (3.9)	2 (1.5)	7 (2.7)
Vascular disorders	5 (3.9)	8 (6.2)	13 (5.0)

Primary system organ classes are presented alphabetically.

A patient with multiple occurrences of an AE under one treatment is counted only once in the AE category for that treatment.

A patient with multiple AEs within a primary system organ class is counted only once in the primary system organ class total row.

MedDRA Version 14.1 has been used for the reporting of adverse events.

Most Frequently Reported AEs Overall by Preferred Term n (%)

Number (%) of patients reporting most frequent AEs (greater than or equal to 1% in any treatment group) by preferred term (Safety set)

Preferred Term	QAX576 N=129 n (%)	Placebo N=130 n %	Total N=259 n %
Number of subjects with at least one AE	75 (58.1)	79 (60.8)	154 (59.5)
Asthma	47 (36.4)	48 (36.9)	95 (36.7)
Nasopharyngitis	15 (11.6)	11 (8.5)	26 (10.0)
Bronchitis	7 (5.4)	4 (3.1)	11 (4.2)
Pharyngitis	6 (4.7)	4 (3.1)	10 (3.9)
Headache	5 (3.9)	7 (5.4)	12 (4.6)
Lower respiratory tract infection	5 (3.9)	4 (3.1)	9 (3.5)
Urinary tract infection	4 (3.1)	2 (1.5)	6 (2.3)
Sinusitis	3 (2.3)	3 (2.3)	6 (2.3)
Upper respiratory tract infection	3 (2.3)	3 (2.3)	6 (2.3)
Nausea	3 (2.3)	0 (0.0)	3 (1.2)

A patient with multiple occurrences of an AE under one treatment is counted only once in the AE category.

Preferred terms are sorted by descending order of incidence in the QAX576 group

Serious Adverse Events and Deaths
Deaths, other serious or clinically significant adverse events or related discontinuations – n (%) of patients (Safety set)

	QAX576 N=129 n %	Placebo N=130 n %	Total N=259 n %
Subjects who died	0	0	0
Subjects with at least one AE	75 (58.1)	79 (60.8)	154 (59.5)
Subjects with at least one SAE	3 (2.3)	8 (6.2)	11 (4.2)
Subjects who discontinued from study due to AEs	3 (2.3)	2 (1.5)	5 (1.9)
Discontinued from study due to SAEs	1 (0.8)	1 (0.8)	2 (0.8)
Discontinued from study due to non-serious AEs	2 (1.6)	1 (0.8)	3 (1.2)

Other Relevant Findings
Date of Clinical Trial Report

27-Sep-2012

Date Inclusion on Novartis Clinical Trial Results Database

19-Feb-2013

Date of Latest Update